Literature DB >> 11698271

Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia.

J M Croop1, R Cooper, C Fernandez, V Graves, S Kreissman, H Hanenberg, F O Smith, D A Williams.   

Abstract

A potential therapeutic option for patients with Fanconi anemia is collection of peripheral blood stem cells prior to the development of severe pancytopenia. These hematopoietic cells potentially could be infused when symptomatic bone marrow failure develops, as autologous rescue after chemotherapy in the event of leukemic transformation, or as targets for gene therapy. Eight patients with Fanconi anemia were mobilized with 10 microg/kg per day of granulocyte colony-stimulating factor (median, 10 +/- 4 days) to determine the feasibility of collecting peripheral blood stem cells for future use. Six patients achieved a peripheral blood CD34+ count of > or = 6/microL and underwent apheresis. The collection goal was 2 x 10(6) CD34+ cells/kg based on a predicted weight 5 years from the date of collection. A mean of 2.6 +/- 0.9 x 10(6) CD34+ cells/kg of the weight at the time of collection were collected, which corresponded to 1.9 +/- 0.4 x 10(6) CD34+ cells/kg of the target weight. The collections required a mean of 4 +/- 3 days (range, 2-8 days) of apheresis. Six of the 8 subjects had > or = 1 x 10(6) CD34+ cells/kg cryopreserved based on both actual and target weights, and 4 subjects had > or = 2 x 10(6) CD34+ cells/kg cryopreserved based on the target weight. These results suggest that some patients with Fanconi anemia can have adequate numbers of CD34+ cells mobilized and collected from the peripheral blood prior to the onset of severe bone marrow failure, but they may require an extended mobilization and multiple days of collection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698271     DOI: 10.1182/blood.v98.10.2917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  On how Rac controls hematopoietic stem cell activity.

Authors:  J A Cancelas
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

2.  Gene therapy for Fanconi anemia: one step closer to the clinic.

Authors:  Jakub Tolar; Pamela S Becker; D Wade Clapp; Helmut Hanenberg; Cristina Díaz de Heredia; Hans-Peter Kiem; Susana Navarro; Pankaj Qasba; Paula Rio; Manfred Schmidt; Julián Sevilla; Els Verhoeyen; Adrian J Thrasher; Juan Bueren
Journal:  Hum Gene Ther       Date:  2012-02       Impact factor: 5.695

3.  Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.

Authors:  Yue Si; Samantha Ciccone; Feng-Chun Yang; Jin Yuan; Daisy Zeng; Shi Chen; Henri J van de Vrugt; John Critser; Fre Arwert; Laura S Haneline; D Wade Clapp
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

Review 4.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

5.  Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice.

Authors:  Yan Li; Wen Xing; Yong-Zheng He; Shi Chen; Steven D Rhodes; Jin Yuan; Yuan Zhou; Jun Shi; Jie Bai; Feng-Kui Zhang; Wei-Ping Yuan; Tao Cheng; Ming-Jiang Xu; Feng-Chun Yang
Journal:  Stem Cell Investig       Date:  2014-10-31

6.  Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A.

Authors:  Xiaoling Zhang; Xun Shang; Fukun Guo; Kim Murphy; Michelle Kirby; Patrick Kelly; Lilith Reeves; Franklin O Smith; David A Williams; Yi Zheng; Qishen Pang
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

7.  Fanca-/- hematopoietic stem cells demonstrate a mobilization defect which can be overcome by administration of the Rac inhibitor NSC23766.

Authors:  Michael D Milsom; Andrew W Lee; Yi Zheng; Jose A Cancelas
Journal:  Haematologica       Date:  2009-06-02       Impact factor: 9.941

8.  Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients.

Authors:  Ariana Jacome; Susana Navarro; Paula Río; Rosa M Yañez; Africa González-Murillo; M Luz Lozano; Maria Luisa Lamana; Julian Sevilla; Teresa Olive; Cristina Diaz-Heredia; Isabel Badell; Jesus Estella; Luis Madero; Guillermo Guenechea; José Casado; Jose C Segovia; Juan A Bueren
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection.

Authors:  Christopher C Porter; James DeGregori
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

10.  CXCR4 induction in hematopoietic progenitor cells from Fanca(-/-), -c(-/-), and -d2(-/-) mice.

Authors:  Amy M Skinner; S Lee O'Neill; Markus Grompe; Peter Kurre
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.